CE Mark for novolimus eluting coronary stent system

Published date : 07 September 2012
Article date : 05 September 2012

 

A report states that Elixir Medical has gained CE Mark approval for the DESyne BD novolimus eluting coronary stent system for the treatment of coronary artery disease.

According to the manufacturer, the device has an ultrathin (< 3 microns) biodegradable, polylactide-based polymer coating that does not need an underlying primer layer. Apparently, Elixir's therapeutic compound, Novolimus, is delivered via the polylactide-based polymer to the coronary vessel wall and degrades within 6 to 9 months, leaving behind the cobalt chromium alloy metal stent surface.

The article says that during a trial, the Elixir DESyne BD novolimus eluting coronary stent system was compared with the control Endeavor Zotarolimus eluting coronary stent system. The former demonstrated superiority over the Endeavor stent for the primary endpoint of in-stent late lumen loss at six months. There was also a statistical difference in favour of DESyne BD for the secondary end point of binary restenosis.

The manufacturer reports that the device will be made available in a broad range of sizes. 

Source: medicaldevice-network.com, 30 August 2012

Read the full article here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.